Lantronix Director Awarded Routine RSU Grant
LANTRONIX INC
Subscribe to track LTRX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Lantronix Director Awarded Routine RSU Grant
Company: LANTRONIX INC (LTRX) Form: 4 | Filed: 2025-11-06 Significance: Low
Insider: Auker James Chris Title: null | Relationship: Director
Transaction: • Type: Grant • Shares: 17,081 (Restricted Stock Units) • Price: $0.00 • Value: $0 • Owned After: 10,387 common shares, 17,081 RSUs
Key Insight: A director received a routine RSU grant as part of their compensation. The filing also notes the vesting of a separate, prior grant of 10,387 shares.
Market Context: The new grant represents a potential future dilution of just 0.044% of shares outstanding for the $180M market cap company, which is considered immaterial.
Comprehensive Analysis
SEC Filing Analysis: LANTRONIX INC (LTRX)
Executive Summary
- Trading Significance: Low
- Key Takeaway: A director at Lantronix received a routine grant of 17,081 Restricted Stock Units (RSUs) as part of their compensation package. A separate transaction in the same filing shows the vesting of 10,387 previously awarded RSUs into common stock.
- Market Impact: Minimal. This is a standard compensation practice with a negligible dilution effect on existing shareholders.
Company Information
| Field | Value |
|---|---|
| Company | LANTRONIX INC |
| Ticker Symbol | LTRX |
| CIK | 0001114925 |
| Industry | Computer Communications Equipment |
Insider Information
| Field | Value |
|---|---|
| Name | Auker James Chris |
| CIK | 0002076945 |
| Title/Position | null |
| Relationship | Director |
Transaction Details
This filing reports two primary events: a new grant and the vesting of a prior grant. The details below focus on the new grant.
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-11-04 |
| Transaction Code | A (Grant) |
| Security Type | Restricted Stock Units |
| Shares Involved | 17,081 |
| Price Per Share | $0.00 |
| Total Value | $0 |
| Shares Owned After | 17,081 (of this RSU grant) |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $0 |
| % of Market Cap | 0.00% |
| Shares Transacted | 17,081 (RSUs) |
| % of Shares Outstanding | 0.044% |
| Post-Transaction Ownership | 10,387 common shares (0.027% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: For a company with a $180 million market cap, this equity grant is a standard and immaterial component of director compensation.
- Ownership Concentration: Following the vesting of a separate award, the director's direct ownership in common stock is 10,387 shares, or just 0.027% of the company, which is not a significant stake.
- Dilution Impact: The potential dilution from the new grant of 17,081 RSUs is approximately 0.044% of total shares outstanding, a negligible impact for existing shareholders.
- Transaction Significance: The transaction is rated Low significance as it is a routine compensation grant representing a very small fraction of the company's equity.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: Equity grants to directors are a common form of compensation and do not typically signal new information or a change in insider outlook.
Volume & Sentiment
- Expected Volume Impact: None. The grant is an off-market transaction.
- Sentiment Indicator: Neutral. This is a routine corporate governance event.
Additional Context
Transaction Notes
- The filing covers two distinct events:
- A new grant of 17,081 RSUs on Nov 4, 2025, which vest over the following year.
- The vesting of 10,387 RSUs on Nov 5, 2025, from a previous grant, which converted into common stock.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
